Statin Therapy In Patients With Vasospastic Angina (STAVA)

Seung-Jung Park

Status and phase: Withdrawn; Phase 4

Conditions: Statins, HMG-CoA; Angina Pectoris, Variant

Treatments: Drug: Placebo; Drug: Atorvastatin

Study type: Interventional

Funder types: Other

Identifiers

NCT02790528

AMCCV2016-11

Details and patient eligibility

About

The purpose of this study is to evaluate whether statin is effective in the treatment of vasospastic angina.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 19 and more
• Vasospastic angina
• LDL less than 160mg/dl
• Written consent

Exclusion criteria

• Coronary artery stenosis more than 50% or ischemic coronary disease
• History of percutaneous coronary intervention
• Cerebrovascular diseases or peripheral
• Dyslipidemia required statin therapy
• Heart failure, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy, akinesia or aneurysm on left ventricular wall, anomaly of coronary artery
• NYHA III and IV
• Arrhythmia
• Primary cardiac electrical diseases
• Cardiac pacemaker or implantable defibrillator
• Pregnancy or breast feeding
• Life expectancy less than 2 years

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Atorvastatin

Experimental group

Description:

20mg QD

Treatment:

Drug: Atorvastatin

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo